
Novo Nordisk has concluded a phase III study, dubbed Onwards 2, of once-weekly insulin icodec, the company has announced in a Thursday press release.
The drug was compared to Novo’s long-acting insulin degludec, which is sold under brand name Tresiba and administered once daily. According to results, icodec is as good as degludec.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app